Close Menu

NEW YORK – Fulgent Genetics reported after the close of the market on Monday that its third quarter revenues rose 84 percent year over year driven by a strong increase in billable tests.

For the three-month period ended Sept. 30, the Temple City, California-based company posted revenues of $10.3 million compared with $5.6 million a year ago. The number of billable tests delivered in the quarter grew 272 percent to 20,697, Fulgent said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.